Radioactive iodine (RAI) is a therapy used in the treatment of some thyroid cancers, specifically papillary and follicular thyroid cancer. For the thyroid gland to make thyroid hormone, the first step in the process is for the thyroid cells to "take up" iodide from the bloodstream. Iodide is one of the building blocks used to produce thyroid hormone. By making the iodine radioactive (in the form of I-131), it becomes toxic to cells that accumulate iodine from the bloodstream, in turn killing these cells. This therapy can be used for several purposes:
Given the potential benefits of RAI, it may seem like something all patients with thyroid cancer should receive. However, RAI does have potential side effects to consider. In addition,patients with larger, more aggressive or residual tumor after surgery have been shown to derive a survival benefit with RAI, but those with smaller, less aggressive cancers have not.
RAI for remnant ablation destroys any residual normal thyroid tissue, allowing your physicians to more easily detect if your thyroid cancer comes back. A blood test called thyroglobulin is used in surveillance monitoring of thyroid cancer. Thyroglobulin is a protein that is only produced by either normal thyroid cells or thyroid cancer cells. After surgery you may still have a small amount of normal thyroid cells remaining (thyroid remnant) in your neck. This is because it is difficult to safely remove the entire thyroid without damaging nearby structures, such as the vocal cords. Therefore, there may be some thyroglobulin, produced by these cells, circulating in your blood. However, after the thyroid remnant is destroyed by RAI, these normal cells are no longer contributing to thyroglobulin production. In the future, if thyroglobulin is detected in your blood, your physician knows that it must be produced by residual or recurrent thyroid cancer. In addition, RAI ablation of the thyroid remnant typically allows for clearer pictures (during radiology scans) of your neck in the future. However, many low-risk patients are followed without having received remnant ablation.
Some thyroid cancer cells also share the same ability as normal thyroid cells to take up iodine from the bloodstream,. These are referred to as "iodine-avid". If your cancer cells are able to do this, then I-131 may also destroy microscopic residual thyroid cancer cells or be used as a treatment for thyroid cancer that has spread to lymph nodes or other areas of the body. Doctors cannot tell by simply looking at the thyroid cells under the microscope if they can take up iodine. Determination of whether a patient's thyroid cancer is iodine-avid depends on many factors such as the type of cancer and results of imaging studies, including whole body scans (see section on Treatment Procedure below).
Although I-131 is a pill, you cannot simply take the pill without prior preparation. To prepare you for I-131 therapy and to maximize the effects I-131, there are 2 things that must happen.
First, you must follow a low iodine diet for 1-2 weeks to deplete your body of iodine. Iodine is found in many foods that we eat. This will make your thyroid cells "hungry" for the I-131 and help to increase the amount of I-131 that gets taken up.
Second, the blood level of a hormone called TSH (thyroid stimulating hormone) must be high. TSH is what signals the thyroid cells to produce thyroid hormone and, as discussed above, the first step in thyroid hormone production is for the thyroid cells to take up iodide from the bloodstream. Therefore, to maximize the amount of I-131 that enters the thyroid cells, your TSH level must be high.
There are two ways to raise your TSH blood concentration and your medical team will advise you as to which method they will use.
Prior to treatment, patients will have a "whole body scan" that is performed one day after taking a small dose of a different radioiodine isotope (I-123). I-123 does not destroy thyroid cells and will allow your treatment team to visualize the location and amount of any remaining thyroid remnant and possibly thyroid cancer. After the whole body scan is completed, you will then receive the oral I-131 treatment pill. After taking the I-131, you will be sent home or, rarely, you may be required to remain in the hospital for a few days. You will be asked to return to the nuclear medicine department 7-10 days later to have another whole body scan, also known as the "post-therapy scan," that will show where the I-131 was deposited in your body. This scan may also identify any new sites of iodine-avid thyroid cancer not seen on the first whole body scan.
I-131 remains in your system for up to a few weeks and excess not taken up by the thyroid is excreted in urine, stool, saliva and perspiration over the first 1-2 days following treatment. As the radioactivity of the I-131 in your system is a concern for those around you, you need to follow radiation safety precautions after receiving I-131. The length of time one has to follow these precautions is partly dependent on the dose of I-131, so the following recommendations need to be individualized. To keep those around you safe, in general, you should stay 3 feet away from them for the first 5 days (10 feet away for the first 24 hours) In addition your team will provide you with detailed precautions for the first week after treatment, which may include:
Talk with your treatment team if you cannot follow any of these instructions due to your personal situation. Ask them about when it is safe to return to work or school, go out in public or when longer distance travel is safe. For up to 2 months,, the radiation you were treated with can set off detectors at airports and other security checkpoints. Talk with your team if you need to travel within this time frame.
National Cancer Institute Thyroid Cancer Page
American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper, D. S., Doherty, G. M., Haugen, B. R., Kloos, R. T., Lee, S. L., et al. (2009). Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid : 19(11), 1167-1214.
American Thyroid Association Taskforce On Radioiodine Safety, Sisson, J. C., Freitas, J., McDougall, I. R., Dauer, L. T., Hurley, J. R., et al. (2011). Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I : Practice recommendations of the american thyroid association. Thyroid :, 21(4), 335-346.
Jonklaas, J., Cooper, D. S., Ain, K. B., Bigos, T., Brierley, J. D., Haugen, B. R., et al. (2010). Radioiodine therapy in patients with stage I differentiated thyroid cancer. Thyroid :, 20(12), 1423-1424.
Miller, B. S., & Doherty, G. M. (2011). An examination of recently revised differentiated thyroid cancer guidelines. Current Opinion in Oncology, 23(1), 1-6.
O'Neill, C. J., Oucharek, J., Learoyd, D., &Sidhu, S. B. (2010). Standard and emerging therapies for metastatic differentiated thyroid cancer. The Oncologist, 15(2), 146-156.
Spiegel, A. M., & Libutti, S. K. (2010). Future diagnostic and therapeutic trends in endocrine cancers. Seminars in Oncology, 37(6), 691-695.
OncoLink is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through OncoLink should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem or have questions or concerns about the medication that you have been prescribed, you should consult your health care provider.
Information Provided By: www.oncolink.org | © 2016 Trustees of The University of Pennsylvania